[1] Gadallah, M.A., Mokhtar, A., Rady, M., El-Moghazy, E., Fawzy, M. and Kandil, S.K., 2016. Prognostic factors of treatment among patients with multidrug-resistant tuberculosis in Egypt. Journal of the Formosan Medical Association, 115(11), pp.997-1003.
[2]World Health Organization, 2018. Compendium of WHO guidelines and associated standards: ensuring optimum delivery of the cascade of care for patients with tuberculosis.
[3]Sulis, G., Centis, R., Sotgiu, G., D’Ambrosio, L., Pontali, E., Spanevello, A., Matteelli, A., Zumla, A. and Migliori, G.B., 2016. Recent developments in the diagnosis and management of tuberculosis. NPJ primary care respiratory medicine, 26(1), pp.1-8.
[4]Bouti, K., Aharmim, M., Marc, K., Soualhi, M., Zahraoui, R., Benamor, J., Bourkadi, J.E. and Iraqi, G., 2013. Factors influencing sputum conversion among smear-positive pulmonary tuberculosis patients in Morocco. ISRN pulmonology, 2013.
[5]World Health Organization, 2016. The shorter MDR-TB regimen features of the shorter MDR-TB regimen, World Health Organization. Available at: http://www.who.int/tb/Short_MDR_regimen_factsheet.pdf.
[6]Liu, Q., Lu, P., Martinez, L., Yang, H., Lu, W., Ding, X. and Zhu, L., 2018. Factors affecting time to sputum culture conversion and treatment outcome of patients with multidrug-resistant tuberculosis in China. BMC infectious diseases, 18(1), p.114.
[7]Kurbatova, E.V., Cegielski, J.P., Lienhardt, C., Akksilp, R., Bayona, J., et al., 2015. Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies. The Lancet Respiratory medicine, 3(3), pp.201-209.
[8]World Health Organization, 2013. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis: interim policy guidance (No. WHO/HTM/TB/2013.6). World Health Organization.
[9]Schnippel, K., Rosen, S., Shearer, K., Martinson, N., Long, L., Sanne, I. and Variava, E., 2013. Costs of inpatient treatment for multi‐drug‐resistant tuberculosis in South Africa. Tropical Medicine & International Health, 18(1), pp.109-116.
[10]Marahatta, S.B., 2010. Multi-drug resistant tuberculosis burden and risk factors: an update. Kathmandu University medical journal, 8(1), pp.116-125.
[11]Pefura-Yone, E.W., Kengne, A.P., Kuaban, C., 2014. Non-conversion of sputum culture among patients with smear positive pulmonary tuberculosis in Cameroon: A prospective cohort study. BMC Infectious Diseases 14. doi:10.1186/1471-2334-14-138
[12]Velayutham, B., Nair, D., Kannan, T., Padmapriyadarsini, C., Sachdeva, K.S., Bency, J., Klinton, J.S., Haldar, S., Khanna, A., Jayasankar, S. and Swaminathan, S., 2016. Factors associated with sputum culture conversion in multidrug-resistant pulmonary tuberculosis. The International Journal of Tuberculosis and Lung Disease, 20(12), pp.1671-1676.
[13] Ige, O.M., Oladokun, R.E., 2018. Time to sputum culture conversion and treatment outcome among the first cohort of multidrug resistant tuberculosis patients in a high burden country. Indian Journal of Tuberculosis 65, 322–328. doi:10.1016/j.ijtb.2018.07.006
[14] Ndwandwe, Z. S., Mahomed, S., Lutge, E., & Knight, S. E. (2014). Factors affecting non-adherence to tuberculosis treatment in uMgungundlovu Health District in 2010. Southern African Journal of Infectious Diseases, 29(2), 56-59.
[15] de Boer, R.N., e Souza, J.B.D.O., Cobelens, F., de Paula Ramalho, D., Miranda, P.F.C., de Logo, K., Oliveira, H., Mesquita, E., Oliveira, M.M. and Kritski, A., 2014. Delayed culture conversion due to cigarette smoking in active pulmonary tuberculosis patients. Tuberculosis, 94(1), pp.87-91.
[16] Qazi, F., Khan, U., Khowaja, S., Javaid, M., Ahmed, A., Salahuddin, N., Hussain, H., Becerra, M.C., Golub, J.E. and Khan, A.J., 2011. Predictors of delayed culture conversion in patients treated for multidrug-resistant tuberculosis in Pakistan. The International journal of tuberculosis and lung disease, 15(11), pp.1556-1560.
[17] World Health Organization, 2014. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. Switzerland: WHO Library Cataloguing-in-Publication Data. 9-167.
[18] Javaid, A., Shaheen, Z., Shafqat, M., Khan, A.H. and Ahmad, N., 2017. Risk factors for high death and loss-to-follow-up rates among patients with multidrug-resistant tuberculosis at a programmatic management unit. American journal of infection control, 45(2), pp.190-193.
[19]World Health Organization, 2015. Guide to Monitoring and Evaluation for Collaborative TB/HIV Activities--2015 Update. World Health Organization.
[20]Adeiza, M., Okpapi, J., Abba, A., 2014. HIV-Associated tuberculosis: A Sub-Saharan African perspective. Sub-Saharan African Journal of Medicine 1, 1. doi:10.4103/2384-5147.129299
[21]Brust, J.C., Lygizos, M., Chaiyachati, K., Scott, M., van der Merwe, T.L., Moll, A.P., Li, X., Loveday, M., Bamber, S.A., Lalloo, U.G. and Friedland, G.H., 2011. Culture conversion among HIV co-infected multidrug-resistant tuberculosis patients in Tugela Ferry, South Africa. PloS one, 6(1).
[22]Chuang, P.H., Wu, M.H., Fan, S.Y., Lin, K.Y. and Jou, R., 2016. Population-based drug resistance surveillance of multidrug-resistant tuberculosis in Taiwan, 2007-2014. PloS one, 11(11), p.e0165222
[23]Moodley, R., & Godec, T. R. (2016). Short-course treatment for multidrug-resistant tuberculosis: the STREAM trials. European Respiratory Review, 25(139), 29-35
[24]Basit, A., Ahmad, N., Khan, A.H., Javaid, A., Sulaiman, S.A.S., Afridi, A.K., Adnan, A.S., ul Haq, I., Shah, S.S., Ahadi, A. and Ahmad, I., 2014. Predictors of two months culture conversion in multidrug-resistant tuberculosis: findings from a retrospective cohort study. PloS one, 9(4).
[25] Kweza, P.F., Van Schalkwyk, C., Abraham, N., Uys, M., Claassens, M.M. and Medina-Marino, A., 2018. Estimating the magnitude of pulmonary tuberculosis patients missed by primary health care clinics in South Africa. The International Journal of Tuberculosis and Lung Disease, 22(3), pp.264-272.
[26] Sharma, S.K. and Mohan, A., 2013. Tuberculosis: From an incurable scourge to a curable disease-journey over a millennium. The Indian journal of medical research, 137(3), p.455.